Author + information
- Received May 15, 2015
- Revision received August 17, 2015
- Accepted August 27, 2015
- Published online December 21, 2015.
- Lai Wei, MD∗,
- Huan Liu, MD∗,
- Liming Zhu, MD∗,
- Ye Yang, MD∗,
- Jiayu Zheng, MD∗,
- Kefang Guo, MD†,
- Hong Luo, MD†,
- Weipeng Zhao, MD‡,
- Xue Yang, MD§,
- Aikebaier Maimaiti, MD∗ and
- Chunsheng Wang, MD∗∗ ()
- ∗Department of Cardiovascular Surgery, Shanghai Cardiovascular Institution and Zhongshan Hospital, Fudan University, Shanghai, China
- †Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China
- ‡Department of Echocardiography, Shanghai Cardiovascular Institution and Zhongshan Hospital, Fudan University, Shanghai, China
- §Department of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China
- ↵∗Reprint requests and correspondence:
Dr. Chunsheng Wang, Department of Cardiovascular Surgery, Shanghai Cardiovascular Institution and Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai 200032, China.
Objectives This study introduces a newly designed transcatheter aortic valve system, the J-Valve system, and evaluates its application in patients with predominant aortic regurgitation without significant valve calcification. We also report the early results of one of the first series of transapical implantations of this device and aim to offer guidance on the technical aspects of the procedure.
Background Transcatheter aortic valve replacement (TAVR) has been widely used in high-risk patients for surgical aortic valve replacement. However, the majority of the TAVR devices were designed for aortic valve stenosis with significant valve calcification.
Methods Six patients with native aortic regurgitation without significant valve calcification (age, 61 to 83 years; mean age, 75.50 ± 8.14 years) underwent transapical implantation of the J-Valve prosthesis (JieCheng Medical Technology Co., Ltd., Suzhou, China), a self-expandable porcine valve, in the aortic position at our institution. All patients were considered to be prohibitive or high risk for surgical valve replacement (logistic EuroSCORE [European System for Cardiac Operative Risk Evaluation], 22.15% to 44.44%; mean, 29.32 ± 7.70%) after evaluation by an interdisciplinary heart team. Procedural and clinical outcomes were analyzed.
Results Implantations were successful in all patients. During the follow-up period (from 31 days to 186 days, mean follow-up was 110.00 ± 77.944 days), only 1 patient had trivial prosthetic valve regurgitation, and none of these patients had paravalvular leak of more than mild grade. There were no major post-operative complications or mortality during the follow-up.
Conclusions Our study demonstrated the feasibility of transapical implantation of the J-Valve system in high-risk patients with predominant aortic regurgitation.
- aortic valve insufficiency
- minimally invasive surgical procedures
- transcatheter aortic valve replacement
The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Wei and Liu contributed equally to this work.
- Received May 15, 2015.
- Revision received August 17, 2015.
- Accepted August 27, 2015.
- American College of Cardiology Foundation